Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 100%High 0 · 0%

Fixed‐dose combination aclidinium/formoterol vs formoterol

Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with formoterol (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 0.76 [0.45, 1.28]
3 studies · 2694 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs placebo

Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with placebo (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 0.55 [0.25, 1.18]
2 studies · 1960 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs aclidinium alone

Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with aclidinium alone (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 0.62 [0.29, 1.29]
2 studies · 2156 participants
Moderate